Cancer Immunity - Volume 5 Supplement 1

Volume 5 Supplement 1

2005

Table of Contents

Cancer Vaccines 2004
The Next Decade, A Report From The World

October 4 - 6, 2004
New York, USA

Sponsored by the Cancer Research Institute and the Ludwig Institute for Cancer Research

Monday, October 4, 2004

Introduction

COMMENTARY
Cancer Vaccines 2004 opening address: The molecular and cellular basis of cancer immunosurveillance and immunoediting
Robert D. Schreiber
Cancer Immunity 5 Suppl 1 : 1 (6 April 2005) >Full text >PDF

Experimental Cancer Immunology

MEETING ABSTRACT
Natural and synthetic antigenic ligands of NKT cells and their role in anti-tumor rejection
Albert Bendelac
Cancer Immunity 5 Suppl 1 : 2 (6 April 2005) >Abstract >PDF

MEETING ABSTRACT
Role of NKT cells to assist priming of antigen-specific T-cell response
Vincenzo Cerundolo
Cancer Immunity 5 Suppl 1 : 3 (6 April 2005) >Abstract >PDF

MEETING ABSTRACT
Natural CD4+ regulatory T cells in tumor immunity
Shimon Sakaguchi, Tomoyuki Yamaguchi, Tomohisa Nishioka, Kwibeom Ko, Sayuri Yamazaki, Kyoko Nakamura, Keiji Hirota, and Takashi Nomura
Cancer Immunity 5 Suppl 1 : 4 (6 April 2005) >Abstract >PDF

MEETING ABSTRACT
Regulatory T cells recognizing SEREX-defined selfantigens in anti-tumor immune response
Hiroshi Shiku
Cancer Immunity 5 Suppl 1 : 5 (6 April 2005) >Abstract >PDF

MEETING ABSTRACT
NKG2D-mediated immune responses
Lewis L. Lanier
Cancer Immunity 5 Suppl 1 : 6 (6 April 2005) >Abstract >PDF

MEETING ABSTRACT
Targeting tumor stroma to destroy cancer variants
Hans Schreiber, Michael T. Spiotto, and Donald A. Rowley
Cancer Immunity 5 Suppl 1 : 7 (6 April 2005) >Abstract >PDF

MEETING ABSTRACT
"Magic bullets" against cancer cells in cancer-resistant SR/CR mice
Zheng Cui
Cancer Immunity 5 Suppl 1 : 8 (6 April 2005) >Abstract >PDF

Tuesday, October 5, 2004

Human Cancer Immunology and Cancer Vaccine Development

MEETING ABSTRACT
Blockade of T cell inhibitory signals: a new paradigm in tumor immunotherapy?
James P. Allison
Cancer Immunity 5 Suppl 1 : 9 (6 April 2005) >Abstract >PDF

MEETING ABSTRACT
Relevance of NKG2D and its ligands in tumor immunity
Thomas Spies
Cancer Immunity 5 Suppl 1 : 10 (6 April 2005) >Abstract >PDF

MEETING ABSTRACT
Specific immunogenicity of heat shock protein-peptide complexes: new developments
Pramod Srivastava
Cancer Immunity 5 Suppl 1 : 11 (6 April 2005) >Abstract >PDF

MEETING ABSTRACT
Vaccine strategies against NY-ESO-1 in cancer patients
Elke Jäger
Cancer Immunity 5 Suppl 1 : 12 (6 April 2005) >Abstract >PDF

MEETING ABSTRACT
NY-ESO-1 protein-based cancer vaccines: the Melbourne experience
Ian D. Davis, Weisan Chen, Max Schnurr, Wendie Hopkins, Lena Miloradovic, Lloyd J. Old, Eugene Maraskovsky, and Jonathan S. Cebon
Cancer Immunity 5 Suppl 1 : 13 (6 April 2005) >Abstract >PDF

MEETING ABSTRACT
Comprehensive analysis of T-cell responses after vaccination with NY-ESO-1 protein
Weisan Chen, Heather Jackson, Nektaria Dimopoulos, Tsin Yee Tai, Nicole A. Mifsud, Qiyuan Chen, Lena Miloradovic, Eugene Maraskovsky, Lloyd J. Old, Ian D. Davis, and Jonathan S. Cebon
Cancer Immunity 5 Suppl 1 : 14 (6 April 2005) >Abstract >PDF

MEETING ABSTRACT
Possible mechanisms of tumor regression after vaccination with MAGE antigens
Pierre G. Coulie, Christophe Lurquin, Bernard Lethé, Nicolas van Baren, and Thierry Boon
Cancer Immunity 5 Suppl 1 : 15 (6 April 2005) >Abstract >PDF

MEETING ABSTRACT
Development of cancer vaccines with the MAGE-3 protein
Vincent Brichard
Cancer Immunity 5 Suppl 1 : 16 (6 April 2005) >Abstract >PDF

MEETING ABSTRACT
Danger signals and the development of new cancer vaccine strategies
Djordje Atanackovic
Cancer Immunity 5 Suppl 1 : 17 (6 April 2005) >Abstract >PDF

MEETING ABSTRACT
SSX antigens as cancer vaccines
Danila Valmori
Cancer Immunity 5 Suppl 1 : 18 (6 April 2005) >Abstract >PDF

MEETING ABSTRACT
Cross-presentation: a mechanism used by melanoma cells for the generation of a tumor-specific antigen derived from the matrix metalloproteinase 2
Francine Jotereau
Cancer Immunity 5 Suppl 1 : 19 (6 April 2005) >Abstract >PDF

Wednesday, October 6, 2004

Human Cancer Immunology and Cancer Vaccine Development

MEETING ABSTRACT
Immunity to SOX group B and ZIC2 antigens: novel neuro-ectodermal targets and clinical indicators in small cell lung cancer
Ali Osmay Güre
Cancer Immunity 5 Suppl 1 : 20 (6 April 2005) >Abstract >PDF

MEETING ABSTRACT
Identification and characterization of human hepatocellular carcinoma-associated antigens
Wei-Feng Chen
Cancer Immunity 5 Suppl 1 : 21 (6 April 2005) >Abstract >PDF

MEETING ABSTRACT
Lessons from a pilot clinical trial of vaccine therapy with an NY-ESO-1 peptide of dual MHC class I and II specificities in ovarian cancer
Kunle Odunsi
Cancer Immunity 5 Suppl 1 : 22 (6 April 2005) >Abstract >PDF

MEETING ABSTRACT
Tumor-specific T cells induced in melanoma patients either naturally or by vaccination with peptides, IFA ± CpG oligodeoxynucleotides
Daniel E. Speiser
Cancer Immunity 5 Suppl 1 : 23 (6 April 2005) >Abstract >PDF

MEETING ABSTRACT
Melanoma peptide vaccines: multipeptide approaches for targeting cytotoxic and helper T cells
Craig L. Slingluff Jr.
Cancer Immunity 5 Suppl 1 : 24 (6 April 2005) >Abstract >PDF

MEETING ABSTRACT
Isolating tumor-reactive T cells and making them work in tumor therapy
Phil Greenberg, William Ho, Matthias Wolfl, Ryan Teague, Junko Morimoto, Michelle Dossett, and Joe Blattman
Cancer Immunity 5 Suppl 1 : 25 (6 April 2005) >Abstract >PDF

MEETING ABSTRACT
GM-CSF based cancer vaccines
Glenn Dranoff
Cancer Immunity 5 Suppl 1 : 26 (6 April 2005) >Abstract >PDF

MEETING ABSTRACT
The evolution of poxvirus based cancer vaccines
Dennis Panicali
Cancer Immunity 5 Suppl 1 : 27 (6 April 2005) >Abstract >PDF